Skip to Content
MilliporeSigma
HomeWebinarsThe Road to Approval: Viral Clearance Strategies for Non-Enveloped Viral Vectors

The Road to Approval: Viral Clearance Strategies for Non-Enveloped Viral Vectors



WEBINAR

The updated ICH Q5A(R2) guideline incorporates viral vectors in its viral safety guidance, including the expectation for a viral clearance study for non-enveloped viral vectors. Designing a viral clearance study for a non-enveloped viral vector requires thoughtful consideration of the risk of any adventitious, endogenous or production viruses that might be present as a potential contaminant. Viral clearance steps should be implemented in the manufacturing process that will selectively inactivate or remove potential contaminants without any detrimental impact to the vector. A well-designed viral clearance study will contribute to the assurance of a vector’s overall viral safety on your journey to regulatory approval.

In this webinar, you will learn:

  • How to identify the sources of potential viral contaminants and develop steps in the manufacturing process to selectively remove or inactivate them
  • The differences between designing a viral clearance study for a non-enveloped viral vector versus a study to support a monoclonal antibody or recombinant protein
  • Why a viral clearance study for viral vector may evaluate fewer steps than a study for a monoclonal antibody or recombinant protein
  • The existing principles for evaluation of inactivation, filtration and chromatography steps apply to a clearance evaluation for a viral vector product

Speaker

Kathryn Martin Remington, Ph.D.

Kathryn Martin Remington, Ph.D.

MilliporeSigma

Technical Consultant

Kathryn Martin Remington, Ph.D. is a member of the field technology management group and provides U.S. clients with technical and regulatory support. Kathy joined the organization in 2010 from Catalent Pharma Solutions where she established a viral clearance program. She was also the section head of the viral validation group for Bayer Healthcare. During her nearly 20 years in viral clearance, she has authored a number of publications on the viral safety of biopharmaceuticals. Kathy earned her M.S. and Ph.D. degrees in microbiology from the University of Montana.

Sign In To Continue

To continue reading please sign in or create an account.

Don't Have An Account?